1.
Osada N, Kikuchi J, Koyama D, Kuroda Y, Yasui H, Leverson JD, Furukawa Y. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation. haematol [Internet]. 2021Jul.15 [cited 2022Jul.5];106(11):3008-13. Available from: https://haematologica.org/article/view/haematol.2021.278506